Clinical trials: ST Segment Elevation Myocardial Infarction
ST Segment Elevation Myocardial Infarction (STEMI), Allogeneic Mesenchymal Bone Marrow Cells
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)
The purpose of this study is to assess the safety and tolerability of human allogeneic mesenchymal bone marrow cells (aMBMC) administered intravenously to subjects with ST Segment Elevation Myocardial Infarction (STEMI).
- Trial name
- NCT01770613
- Testing
- Stem cells
- Where
- 2 sites in United States
- Sponsor
- Stemedica Cell Technologies, Inc.
Ischemic Heart Disease, Stable Coronary Artery Disease
To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent
to evaluate safety and efficacy of CGBIO stent(DES) compared to Biomatrix flex stent(DES)
- Conditions
- Ischemic Heart Disease, Stable Coronary Artery Disease, Stable Angina, Unstable Angina
- Trial name
- NCT03089450
- Testing
- CGBio stent, Biomatrix flex
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- CGBio Inc.
ST-segment Elevation Myocardial Infarction
Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients
Evaluate the efficacy, Safety and Pharmacokinetics of Intravenous single injection LC28-0126 immediately before Percutaneous Coronary Intervention (PCI) in Patients with ST-segment Elevation Myocardial Infarction (STEMI).
- Trial name
- NCT02770664
- Testing
- LC28-0126 Dose A, LC28-0126 Dose B, LC28-0126 Dose C
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- LG Life Sciences
ST-segment Elevation Myocardial Infarction
Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients
Evaluate the efficacy, Safety and Pharmacokinetics of Intravenous single injection LC28-0126 immediately before PCI (Percutaneous Coronary Intervention) in Patients with STEMI (ST-segment Elevation Myocardial Infarction)
- Trial name
- NCT02070471
- Testing
- LC28-0126 Dose A, LC28-0126 Dose B, LC28-0126 Dose C
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- LG Life Sciences
ST Segment Elevation Myocardial Infarction
NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction
This study will assess the safety and efficacy of intracoronary artery administered autologous bone marrow derived stem cells in subjects post ST segment elevation myocardial infarction (STEMI).
- Trial name
- PreSERVE-AMI (NCT01495364)
- Testing
- NBS10
- Where
- 58 sites in United States
- Volunteers
- 195 people
- Sponsor
- Lisata Therapeutics, Inc.
ST Segment Elevation Myocardial Infarction
Anfibatide Treatment in STEMI Patients
A Phase IIb clinical trial to investigate the safety and efficacy of antiplatelet thrombolysin injection for patients with ST Segment Elevation Myocardial Infarction (STEMI) before receiving PCI therapy, in order to provide…
- Trial name
- NCT02495012
- Testing
- Anfibatide
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Lee's Pharmaceutical Limited
Non ST Segment Elevation Myocardial Infarction, Unstable Angina
Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation
This non-inferiority study aims at comparing Versa® to the reference enoxaparin (Clexane®, Sanofi-Aventis) in patients with high-risk unstable angina and NSTEMI.
- Trial name
- VECOR (NCT01356992)
- Testing
- Enoxaparin
- Where
- 5 sites in Brazil
- Volunteers
- 62 people
- Sponsor
- Eurofarma Laboratorios S.A.
ST Segment Elevated Myocardial Infarction
OCT Study of the MGuard Prime Stent in Patients With Heart Attacks
The objective is to demonstrate that the Flow Area within a blocked coronary vessel as assessed by OCT is greater with the MGuard Prime stent compared to non-mesh control stent (BMS/DES) in subjects undergoing primary PCI for…
- Trial name
- MASTER-OCT (NCT02222116)
- Testing
- MGuard Prime, Control BMS DES
- Where
- United Kingdom
- Sponsor
- InspireMD
Myocardial Infarction, Acute ST-Segment Elevation
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)
The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after…
- Trial name
- NCT00077792
- Testing
- Enoxaparin sodium (XRP4563)
- Where
- 48 sites in United States, Argentina and 46 more
- Volunteers
- 20,506 people
- Sponsor
- Sanofi